1,624,279 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Acquired by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,624,279 shares of the biotechnology company’s stock, valued at approximately $16,243,000. BioCryst Pharmaceuticals comprises about 1.7% of Parkman Healthcare Partners LLC’s investment portfolio, making the stock its 24th largest holding. Parkman Healthcare Partners LLC owned approximately 0.64% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Royal Bank of Canada increased its position in shares of BioCryst Pharmaceuticals by 2.4% in the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after acquiring an additional 1,458 shares during the period. Cetera Investment Advisers grew its stake in BioCryst Pharmaceuticals by 13.8% during the 4th quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 1,494 shares during the last quarter. Captrust Financial Advisors grew its stake in BioCryst Pharmaceuticals by 7.4% during the 2nd quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 1,527 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 2,115 shares during the period. Finally, Legato Capital Management LLC increased its holdings in shares of BioCryst Pharmaceuticals by 10.0% in the fourth quarter. Legato Capital Management LLC now owns 23,949 shares of the biotechnology company’s stock valued at $187,000 after purchasing an additional 2,172 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on BCRX shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. JPMorgan Chase & Co. initiated coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They issued a “neutral” rating and a $12.00 price target on the stock. Citizens Jmp lifted their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Finally, Royal Bank Of Canada reduced their price target on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX stock opened at $9.68 on Tuesday. The company has a 50-day moving average of $9.64 and a two-hundred day moving average of $8.97. The firm has a market cap of $2.47 billion, a PE ratio of -6.45 and a beta of 0.56. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business had revenue of $218.25 million during the quarter, compared to analysts’ expectations of $183.28 million. During the same period in the previous year, the firm posted $0.15 earnings per share. The company’s revenue was up 33.6% on a year-over-year basis. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.